Novartis Ag (NVS) Net Cash Flow Growth (3y) (2013 - 2025)
Novartis Ag (NVS) Net Cash Flow Growth (3y) (2013 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
33.78% |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
-50.54% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
-45.98% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
54.26% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-44.49% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
-50.46% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
29.14% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
-32.34% |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
-26.50% |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
- |
| Date | Value |
|---|
| Dec 31, 2025 |
37.67% |
| Jun 30, 2025 |
57.30% |
| Dec 31, 2024 |
-7.25% |
| Sep 30, 2024 |
15.16% |
| Jun 30, 2024 |
-47.11% |
| Mar 31, 2024 |
-46.52% |
| Dec 31, 2023 |
48.99% |
| Jun 30, 2023 |
-41.67% |
| Dec 31, 2022 |
-193.07% |
| Jun 30, 2022 |
-288.26% |
| Dec 31, 2021 |
-86.81% |
| Sep 30, 2021 |
-20.87% |
| Jun 30, 2021 |
-43.13% |
| Dec 31, 2020 |
89.96% |
| Jun 30, 2020 |
70.96% |
| Dec 31, 2019 |
34.68% |
| Jun 30, 2019 |
32.07% |
| Sep 30, 2018 |
-4.57% |
| Dec 31, 2017 |
-8,530.75% |
| Sep 30, 2017 |
-12,953.31% |
